By physically interacting with AR NTD, BRD4 plays a critical role in facilitating AR-mediated transcription (56, 57); clinical evaluation of BET inhibitors is currently underway in castration-resistant prostate cancer (clinical trial: NCT03035591). Here, AR is linked to prostate cancer.